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Glen R BrownAbstract
The optimum dosage regimen for cotrimoxazole in the treatment of life threatening infections due to susceptible
organisms encountered in critically ill patients is unclear despite decades of the drug’s use. Therapeutic drug
monitoring to determine the appropriate dosing for successful infection eradication is not widely available.
The clinician must utilize published pharmacokinetic, pharmacodynamic, and effective inhibitory concentration
information to determine potential dosing regimens for individual patients when treating specific pathogens. Using
minimum inhibitory concentrations known to successfully block growth for target pathogens, the pharmacokinetics
of both trimethoprim and sulfamethoxazole can be utilized to establish empiric dosing regimens for critically ill
patients while considering organ of clearance impairment. The author’s recommendations for appropriate dosing
regimens are forwarded based on these parameters.
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Cotrimoxazole, the combination of trimethoprim (TMP)
and sulfamethoxazole (SMX), is frequently required for the
treatment of critically ill patients with infections caused by
sensitive pathogens, such as Pneumocystis jovenii or
Stenotrophomonas maltophilia. As with other antibiotics,
TMP/SMX must be given in a sufficient dose at a proper
frequency to produce adequate concentrations at the site of
infection for successful eradication of the pathogen. TMP/
SMX also has concentration-dependent toxicities, necessi-
tating avoidance of excessive dosage. The determination of
the appropriate dosing regimen requires optimum applica-
tion of the drug’s pharmacokinetics and pharmacodynamic
characteristics. Data from clinical trials of various dosages of
TMP/SMX in the critically ill population are generally
lacking, forcing the clinician to prescribe the drug without
clear knowledge of the appropriate regimen. This paper will
review the available pharmacodynamic and pharmacokinetic
data necessary for the clinician to determine the optimum
dosage of TMP/SMX for selected infections in the critically ill.
Relevant electronic databases of published literature
(Embase, Medline) containing studies of the pharmacokin-
etics, pharmacodynamics, and inhibitory concentrations of
TMP/SMX were searched to end date of 16 September
2013. References of selected manuscripts were reviewed forCorrespondence: gbrown@providencehealth.bc.ca
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in any medium, provided the original work is prelevant citations. References in tertiary information
sources, and the author’s personal information files were
searched for relevant data. The preliminary search yielded
few studies focused specifically on the critically ill popula-
tion. Therefore, studies outlining the pharmacokinetics in
normal and altered organ clearance populations (renal and/
or liver impairment); the pharmacodynamics of TMP/SMX
in any setting; and the minimum inhibitory concentrations,
determined either in vitro or in vivo, were selected. Data
from the selected publications were reviewed to allow an
assessment of the applicability to the critically ill population
and to determine potential dosing regimens for specific
pathogens in critically ill patients.
Pharmacokinetics
The volume of distribution (Vd) for each drug has been
determined in healthy subjects with TMP having a much
larger volume of distribution than SMX based on differences
in lipid solubility [1]. There are only very limited data avail-
able on the impact of critical illness on the Vd of the two
drugs, despite the widely recognized changes that occur with
other antibiotics. In critically ill patients requiring mechan-
ical ventilation for Pneumocystis carinii pneumonia, the Vd
of TMP was 1.6 L/kg versus 1.4 L/kg for non-ventilated
patients, and the Vd for SMX was 0.5 L/kg versus 0.4 L/kg
[2]. In trauma patients, although reporting low Acute
Physiology and Chronic Health Evaluation II (APACHE II)
scores of 1 to 24, the Vd of TMP was found to be 2.1 L/kgen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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magnitude of change in Vd of the drugs in patients with
septic shock requiring large volume resuscitation or vaso-
pressors. Data are also lacking on the impact of obesity on
the Vd, and resulting dosing of the drug. Therefore, dosing
regimens should be based on actual body weight.
Both TMP and SMX are eliminated from the body
predominantly by renal excretion [1,4]. Approximately 20%
of SMX is metabolized in the liver to N4-acetylsulfamethox-
azole which is subsequently excreted in the urine [5].
N4-acetylsulfamethoxazole lacks relevant antibacterial ac-
tivity [1]. The remainder of SMX is cleared by the kidney
as unchanged drug [4]. The renal excretion of SMX is
increased when the urine is alkaline [5]. Similarly, only a
small portion of TMP (10 to 20%) is metabolized by the
liver to inactive metabolites, which are subsequently
conjugated and excreted in the urine [1]. The remaining
portion of TMP elimination is via renal secretion of
unchanged drug [4]. Unlike SMX, TMP renal clearance is
increased with acid urine [1].
Achievable concentrations for various dosages are
described in Table 1. The commercially available tablet
contains 80 mg TMP with 400 mg SMX (single strength)
or 160 mg TMP with 800 mg SMX (double strength). An
intravenous preparation is commercially available contain-
ing 16 mg TMP with 80 mg SMX per ml. Both intravenous
(IV) and oral (PO) dosages of 15 mg/kg/day of TMP
produced Cmax concentrations within the target range for
treatment of Pneumocystis jovenii (5 to 8 mcg/ml) [2,6].
Oral dosages of 20 mg/kg/day of TMP produced higher
concentrations which resulted in a high incidence of toxic-
ities [7]. For pathogens with lower target concentrations
(see Target concentrations; Table 2), Cmin concentrations
for TMP of above 2 mcg/ml can be maintained with a
dosage of 160 mg TMP twice daily.
Renal dysfunction
Despite the availability of TMP/SMX for a number of
decades, published data on the optimum dosage of the drug
in patients with renal impairment are unavailable, similar to
many widely used treatments [18]. Early work demon-
strated a linear relationship between the elimination rate of
both unchanged SMX (weak correlation) or TMP (signifi-
cant correlation) and renal function (as measured by inulin
clearance) [8]. The strongest correlation between renal
function and pharmacokinetics was seen with the clearance
of SMX metabolites (inactive), while the unchanged SMX
concentrations remained constant over a wide range of
renal impairment [8,19]. These studies involved patients
with renal impairment resulting in creatinine clearance
rates of 3 to 72 ml/min/1.73 m2 [8,19]. Using the dosage
recommended for normal renal function, similar concentra-
tions of unchanged active SMX from patients with normal
renal function were achieved in patients with severe renalimpairment [8]. Others, however, have found the elimin-
ation of unchanged SMX to be related to renal function,
with an estimation of the half-life possible via calculation:
T1=2 ¼ 39x CrClml=minð Þ−0:29 20½ 
The total amount of SMX (unchanged and metabolites)
recovered in the urine of patients with renal impairment
remains similar to patients with normal renal function
(approximately 80% of an oral dosage), but the portion of
the drug remaining unchanged decreased as renal function
decreased, suggesting increased metabolism as renal func-
tion deteriorates [8]. The magnitude of the increase in
clearance can not be estimated clinically or from published
literature, but may be of relevance in producing drug
concentrations equivalent to patients with normal renal
function. The lack of accumulation of active SMX with renal
impairment has important therapeutic ramifications since
the metabolite does not have antimicrobial activity. If the
SMX dosage is reduced when treating patients with renal
impairment, the concentration of the active unchanged
SMX may decrease, since its clearance is not impaired
and may even increase, and potentially compromise the
therapeutic effect.
The correlation of renal function and TMP clearance has
been verified by other investigators [19,20]. The elimination
half-life of TMP has been found to approximate:
T1=2 ¼ 28x CrClml=minð Þ−0:13 20½ 
Both unchanged drug and the conjugated metabolites of
TMP will accumulate as renal function decreases unless a
dosage reduction is implemented.
Liver dysfunction
The pharmacokinetics of both SMX and TMP are not
altered significantly by liver impairment [5]. The half-life of
both SMX and TMP was not prolonged, versus normal
subjects, in patients with mild or severe liver dysfunction,
although the characterization of the liver function was
poorly defined [21].
The metabolism of SMX appears to be influenced by the
activity of N-acetyltransferase 2 (NAT2), with the existence
of genetic polymorphism altering the activity of the enzyme
[22]. Patients without the native NAT2*4 allele do not clear
SMX as rapidly resulting in accumulation of drug and
increased exposure [22]. However, the published research
methodology does not describe the ability to differentiate
active unaltered SMX from the various metabolites. Since
they found a correlation between drug accumulation and
creatinine clearance, the potential that the finding of
increased exposure in patients without native NAT2*4 could
be due to accumulation of inactive SMX metabolites. No
data exist to describe the effect of critical illness on activity
of NAT2 or the ramifications of dosing of patients with the




















Normal [8] 1 F/3 M 34 66 80 mg TMP PO Q12h × 9 days 1.5 8.2
400 mg SMX 0.26 9.8
Normal [9] N/A 21 to 40 N/A 240 mg TMP IV Q12h × 7 doses 5.91 15 2.64 16.5
1,200 mg SMX 178 78 14.1
Normal [7] 12 M 28 75.8 20.2 mg/kg/day TMP PO Q6h × 13 doses 13.6 114 1.4 13.6 1.05
101.1 mg/kg/day SMX 372 156 0.25 14.0 0.024
Normal [6] 6 M 26.7 73.7 12.6 mg/kg/day TMP PO Q6h × 3 days 8.3 90 6.1 1.78 14.6 0.89
63.3 mg/kg/day SMX 247 108 199 0.27 14.0 0.02
HIV PCP [10] 1 F/22 M 24 to 75 59 15 to 22 mg/kg TMP IV (15) Q6h × 4 to 6 days 7.7
75 to 110 mg/kg SMX PO (8) 198
PCP [2] N/A 37 67.6 16.1 mg/kg/day TMP IV Q6 to 8 h × 2 to 10 days 7.9 15 1.5 11.3 1.73
80.5 mg/kg/day SMX 186 0.4 14.3 0.34
Ventilated N/A 37 68.5 14.7 mg/kg/day TMP IV Q6 to 8 h × 2 to 10 days 8.1 15 1.6 10.9 1.88
PCP [2] 73.4 mg/kg/day SMX 163 0.5 15.5 0.40
Oncology [11] N/A N/A N/A 150 mg/m2 TMP IV Q8h × 24 hours 7.02 65 3.65 9.60
750 mg/m2 SMX 148 88 10.7
Infected 6 F/5 M 60 65 160 mg TMP IV Q8h × 4 days 8.8 60 5.6 0.72 11.3 1.13
Cancer [12] 800 SMX 105.6 70.6 0.27 12.8 0.04
Trauma [3] 2 F/13 M 31 87 8 mg/kg/day TMP IV Q12h 2.1 9.8 2.8
40 mg/kg/day SMX 0.51 8.4 0.75
M, male; F, female; Cmax, maximum concentration within the dosing interval; Tmax, time to reach maximum concentration; Cmin, minimum concentration within
dosing interval.
Vd, volume of distribution; T1/2, calculated half-life; N/A, not available; PO, oral administration; IV, intravenous administration; PCP, Pneumocystis
jovenii pneumonitis.












5 to 8 Cmax 100 to 200 mcg/ml Cmax [13]
Stenotrophomonas
maltophilia
> 6 Cmax > 60 Cmax [14]
Burkholderia
pseudomallei
≥ 2 Cmin ≥ 38 Cmin [15]




≥ 2 Cmin ≥ 38 Cmin [17]
ESBL
Enterobacteriaceae
≥ 2 Cmin ≥ 38 Cmin [17]
Cmax, Maximum concentration during dosing interval.
Cmin, Minimum concentration during dosing interval.
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makeup is not usually known at the time of initiating TMP/
SMX therapy, currently the clinician is unable to assess or
consider the need for dosage adjustments.
Dialysis
Similar to findings in non-dialysis dependent renally
impaired patients, unchanged SMX concentrations do not
increase in patients with renal impairment sufficient to
necessitate dialysis [8]. However, the concentrations of TMP
and of SMX metabolites increased in dialysis-dependent
patients compared to patients with severe non-dialysis
dependent renal impairment [8]. Surprisingly, given the
drug’s prolonged use, only limited description of the effect
of dialysis on removal of each drug during a dialysis session
is available; none for critically ill patients. Pharmacokinetic
evaluation in a single patient during a hemodialysis session
suggested efficient removal of both antibiotics, with total
(unchanged and metabolites) SMX clearance increasing
approximately 3.5-fold over non-dialysis periods (83.9 versus
24.4 ml/min) [23]. Approximately 50% of total (unchanged
and metabolites) SMX and TMP body stores was removed
by a four hour dialysis with a 1 m2 cuprophane dialysis
membrane at a blood flow rate of 200 ml/min and dialysateflow rate of 500 ml/min [24]. These limited data suggest that
hemodialysis is effective in removing SMX metabolites and
TMP. However, since active SMX does not accumulate with
standard dosing in dialysis patients, the optimum dosing of
the combination becomes challenging. Dosage reduction may
compromise the activity of unchanged SMX while standard
Table 3 Selected cotrimoxazole (TMP/SMX) toxicities and
relationship to drug concentration
Idiosyncratic toxicity Concentration dependent toxicity
Allergic skin reaction [31] Apraxia [32]
Cholestasis [33] Delirium [34]
Hemolytic crisis [35] Hyperkalemia [36]
Hepatitis [37] Hypoglycemia [38]
Interstitial nephritis [39] Aseptic meningitis [40]
Methemoglobinemia [41] Metabolic acidosis [42]
MODS [43] Myoclonus [44]
Pancreatitis [45] Psychosis [46]
Parotitis [47] Renal tubular obstruction [48]
Stevens-Johnson syndrome [49] Tremor [50]
Thrombocytopenia [51]
Torsades de pointe [52]
MODS, Multi-organ dysfunction syndrome. Square-bracketed numbers
indicate references.
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metabolites and TMP. A potential approach would be to pro-
vide full dosages for the first 24 to 48 hours with subsequent
dosage reduction based on clinical response [25].
SMX and its metabolites are partially removed by
continuous ambulatory peritoneal dialysis [5], although the
amount cleared would be anticipated to be clinically insig-
nificant [23,26]. Instillation of 2 L of 2.5% glucose periton-
eal dialysis solution four times daily contributed only 7% of
total TMP body clearance and 8% of unchanged SMX
clearance in chronic CAPD patients [27]. SMX metabolites
are similarly poorly removed by CAPD as demonstrated by
a low clearance rate found with four times daily dwells [16].
Rapid cycling peritoneal dialysis at a rate of 3 L/hour
efficiently (60%) removed SMX, but had minimal effects on
TMP clearance [28]. Hence, peritoneal dialysis should not
be considered to reduce the potential for accumulation of
either drug to toxic concentrations, and the remaining renal
function of the patient should guide dosing.
Removal rates during continuous veno-venous hemodiafil-
tration (1.8 m2 high-flux polysulfone filter at blood flow
rates of 180 ml/min, dialysate flow rate of 1,500 ml/hour
and fluid replacement of 1,500 ml/hour) produced clearance
rates for both drugs similar or exceeding normal renal func-
tion [29]. Extended daily dialysis (1.3 m2 high flux polysul-
fone filter at blood flow rates of 140 ml/min, dialysate flow
of 170 ml/min for 440 minutes) resulted in substantial clear-
ance of TMP, with less clearance of SMX, and no report of
clearance of SMX metabolites [30]. These authors caution
clinicians regarding dosing reduction during continuous
veno-venous hemodiafiltration and the potential for such
reduction to result in inadequate drug concentrations [30].
Toxic concentrations
The theoretical benefit of utilizing larger dosages of TMP/
SMX to ensure the adequacy of achievable concentrations
at site of infection must be balanced against the real occur-
rence of side effects due to excessive drug concentrations
(Table 3). Although some TMP/SMX toxicities are predict-
able, such as the development of hyperkalemia and type 4
renal tubule acidosis from TMP inhibition of sodium
channels in the distal nephron, others can not be anti-
cipated. Such unpredictable toxicities are thought to be
concentration-related, based on the offending dosages and
impaired clearance in many affected patients. However, the
concentration required for development of specific toxic-
ities is unknown since the majority of case reports of
concentration-dependent toxicities do not have measured
serum concentrations at the time of symptoms or signs.
However, based on the dosage and the patients’ size and
renal function reported in published cases, concentrations
required to produce the toxicity would be anticipated to
equal or exceed those seen with therapy of 15 mg/kg/day of
TMP. This threshold dosage is based on the only clinicaltrial reporting toxicities with various dosages where dosage
regimens producing higher concentrations (Mean for Cmax
of TMP 13.6 mcg/ml/SMX 372 mcg/ml) produced an
unacceptable incidence of toxicity [7]. Given the large
variety of concentration-related toxicities, the clinician can
not utilize excessive dosages without exposing the patient
to potential risk of toxicity. Similarly, the accumulation of
SMX metabolites in renal failure (see Pharmacokinetics
above) is anticipated to increase the potential for
concentration-related toxicities. However, the balance be-
tween effective doses and doses that will produce toxicities
with renal impairment is not clear. The truly idiosyncratic
toxicities (those that occur at dosages tolerated by the vast
majority of patients) cannot be predicted or avoided
through dose manipulation.
Pharmacodynamics
Both TMP and SMX act by blocking steps in the produc-
tion of metabolically active folate [53]. Sulfonamides act by
blocking the production of dihydrofolate from precursor
components (p-aminobenzoate, pteridine, and glutamate)
[54]. This inhibition is irrelevant for human metabolism
since humans can utilize dihydrofolate absorbed from the
diet while bacteria must manufacture the dihydrofolate
from precursors. TMP works on a subsequent step of
folate metabolism by competitively inhibiting dihydrofolate
reductase, the enzyme responsible for production of the
active tetrahydrofolate [54]. Humans are not adversely af-
fected by the TMP-induced blockage of dihydrofolate
reductase since this enzyme in bacteria is greater than
1,000-fold more sensitive than human dihydrofolate reduc-
tase. Therefore, at concentrations achieved with therapeutic
dosages, two steps in folate metabolism within bacteria are
blocked, while human metabolism is unaffected.
Brown Annals of Intensive Care 2014, 4:13 Page 5 of 9
http://www.annalsofintensivecare.com/content/4/1/13Surprisingly, the determination of the pharmacody-
namic parameter (concentration or time) most related to
bacterial kill has not been clearly determined [55]. TMP/
SMX has variable bacteriostatic and bacteriocidal action.
Early work suggested that TMP/SMX has bacteriocidal
activity against gram positive organisms, such as Staphylo-
coccus aureus [56]. What little available evidence evaluat-
ing concentration versus time killing suggests that TMP/
SMX has concentration-dependent activity against gram-
positive organisms, such as Staphylococcus aureus [54,57].
For gram-negative organisms, it has been hypothesized
that TMP/SMX has concentration-dependent killing of
E. coli, although supporting data are lacking [57]. Early
investigations suggested only bacteriostatic activity with
concentrations achievable in urine due to interaction with
nutrients which inhibit the activity of the drugs [58].
Subsequent limited evaluation suggests that TMP/SMX is
bacteriostatic against sensitive E. coli at concentrations of
2 mcg/ml TMP and 40 mcg/ml SMX, supporting time-
dependent killing [59]. However, others have shown that at
TMP concentrations greater than 2 mcg/ml (>12 mcg/ml
SMX) bacteriocidal activity can be detected [20].
For other organisms, the pharmacodynamics are even less
clear. Limited evidence from Burkholderia pseudomallei
treatment suggests concentration effects through achievable
in vivo concentrations [60]. This concentration-dependent
killing was not long standing, and converted to bacteriostatic
effects when studied using time-kill methodology [60].
Only bacteriostatic activity could be demonstrated against
Nocardia spp. at TMP/SMX concentrations of 3.4/17 mg/L;
a concentration achievable with a 7.5 mg/kg/day TMP dose)
[61].
In summary, TMP/SMX possesses bacteriostatic activity,
which is time dependent, with the potential for concentra-
tion dependent bacteriocidal activity for specific organisms,
possibly in selected infected sites within the body. Since the
pharmacodynamics are unclear, clinicians should select
dosages that would be anticipated to produce adequate
concentrations, as described by successful therapeutic
studies, throughout the dosage interval.
Target concentrations
Pneumocystis jovenii
The target concentrations for inhibition of growth of
Pneumocystis jovenii are thought to span a range of 5 to 8
mcg/ml for TMP and 100 to 200 mcg/ml for SMX at the
maximum (Cmax) concentrations of the dosing interval.
This range is based on early clinical trials in non-HIV
infected patients who had a worse outcome with doses
which were unsuccessful in achieving such steady state
Cmax concentrations [62-64]. Subsequent trials, again in
non-HIV infected patients, demonstrated good clinical
recovery when the TMP/SMX dosage was adjusted to
achieve a TMP Cmax concentration above 5 mcg/ml [65].Dosage regimens producing Cmax concentration within a
range of 5 to 8 mcg/ml for TMP and 100 to 200 mcg/ml for
SMX have been demonstrated to produce more rapid reso-
lution of fever and improvement of alveolar-arterial oxygen-
ation gradient than use of pentamidine [13]. These target
concentrations also demonstrated improved survival when
compared to use of pentamidine [13]. Dosage regimens
producing higher concentrations (mean for Cmax of TMP
13.6 mcg/ml/SMX 372 mcg/ml) have been associated with
an unacceptable incidence of toxicity [7]. These data suggest
target Cmax concentrations within a range of 5 to 8 mcg/ml
for TMP and 100 to 200 mcg/ml for SMX are optimal for
Pneumocystis jovenii treatment.
Stenotrophomonas maltophilia
The target concentrations for eradication of Stenotrophomo-
nas infections are unknown. The Clinical and Laboratory
Standards Institute (CLSI) standard breakpoint for Stenotro-
phomonas sensitivity to TMP/SMX is < 2 mcg/ml for TMP
and 38 mcg/ml for SMX [17]. Approximately 95% of North
American Stenotrophomonas maltophilia strains were sensi-
tive using the CLSI breakpoint when assessed in the late
1990s [66]. However, other investigators have found that the
minimum inhibitory concentration adequate to inhibit 90%
(MIC90) of isolates is as high as 4/76 mcg/ml [67], a concen-
tration still achievable with oral dosing. Higher concentra-
tions may be desirable based on an in vitro model that
showed that Cmax concentrations of 6/60 mcg/ml were not
bacteriocidal, only bacteriostatic [14]. Very high concentra-
tions (32/608 mcg/ml) are required for bacteriocidal activity,
a concentration not achievable or tolerated (see below) [67].
In light of the unlikelihood of achieving bacteriocidal con-
centrations with tolerable doses, serious Stenotrophomonas
infections should be treated with alternative antibiotics, such
as fluoroquinolones or combinations of betalactam or fluor-
oquinolones with TMP/SMX [68]. However, infections
caused by isolates with lower MICs can be successfully
treated, although the optimum serum concentrations have
not yet been determined.
Burkholderia pseudomallei (Melioidosis)
Burkholderia pseudomallei is the causative organism of po-
tentially fatal respiratory infections. The CLSI breakpoints for
B. pseudomallei are < 2 mcg/ml for TMP and < 38 mcg/ml
for SMX [15]. Alternative antibiotics with more favorable
MIC and pharmacodynamics, such as cephalosporins or
carbapenems, should be considered for acute treatment of
serious infections [69]. However, for eradication therapy
requiring up to three months of continuous treatment, oral
TMP/SMX is an effective and attractive option based on
the ease of administering the drug versus parenterally
administered alternatives [69]. Based on pharmacodynamic
evaluation for B. pseudomallei, TMP/SMX was found to be
bacteriostatic, so the concentration should be targeted to
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the serum concentration above the MIC for 60% of the
dosing interval or a 24 hour Area under the concentration
curve/MIC ratio of greater than 25 have been suggested as
a target pharmacokinetic index [60]. This recommendation
has not been tested in a clinical trial evaluating patient
outcome. Alternatively, using the dosage of 160/800 mg
twice daily for three months has been shown to be effective
in eradication of the infection [70].
Nocardia spp.
Nocardia frequently produces life-threatening infections in
immunocompromized patients, particularly following solid-
organ transplantation. The breakpoint for susceptibility for
Nocardia spp. is ≤ 2/38 mg/L TMP/SMX [15]. Resistant
strains of various Nocardia species are frequently encoun-
tered [16,71]. The MIC90 of many of the resistant strains is
4/76 mg/L [16], a concentration only achievable throughout
the dosing interval with high dose TMP/SMX.
Methicillin-resistant Staphylococcus aureus (MRSA)
The CLSI breakpoint for methicillin-resistant Staphylococcus
aureus (MRSA) is identical to that of methicillin-sensitive
strains ≤ 2/38 mcg/ml [17]. The prevalence of resistance of
MRSA to TMP/SMX varies greatly throughout the world,
and may also vary over time within individual institutions,
possibly reflecting frequency of TMP/SMX use [72]. If an
isolate of MRSA is sensitive to TMP/SMX, the antibiotic is
an attractive treatment option. Clinical trials demonstrating
clinical efficacy for TMP/SMX in MRSA infections are
limited [73]. For an isolate deemed sensitive utilizing the
CLSI breakpoint, achievable concentrations with traditional
dosing would be expected to be successful in eradicating the
pathogen. Small clinical trials have shown such success in
treating MRSA bacteremia and other infections, although
drug concentrations were not measured [74,75]. However,
recent data suggesting that TMP/SMX has negligible effect
against intracellular MRSA may limit the clinical utilization
of the antibiotic [76].
Enterobacteriaceae - extended-spectrum β-lactamase-
producing (ESBL) Enterobacteriaceae
TMP/SMX is not altered by beta-lactamases due to the
physical structure of each of the antibiotics composing
TMP/SMX. However, the majority of organisms which
possess the capability to produce ESBLs have also acquired
concurrent mechanisms for resistance to TMP/SMX [77].
For example, only approximately 26% of E. coli ESBL-
producing strains were sensitive to TMP/SMX in a collec-
tion of isolates from across Canada in 2007 to 2009 [78].
Exceeding the Standard CSLI breakpoint concentrations
(≤2/38) would theoretically be adequate for eradication of
sensitive organisms (CSLI). However, evidence supporting
the effectiveness or inadequacy of achieving clinical curewhen using TMP/SMX for ESBL-producing infections is
lacking.
Dosing recommendations in the critically ill
The clinician is frequently placed in a position of uncer-
tainty regarding the MIC of the infecting organism, and
the appropriate dose to achieve the target concentrations
for optimal pharmacodynamics, and resulting efficacy.
Clinical trials to demonstrate the optimal dosing regi-
mens, as discussed above, are generally lacking. The bene-
fit of prospective therapeutic drug monitoring of TMP/
SMX concentrations in critically ill patients has not been
evaluated in the published literature. Intuitively, thera-
peutic drug monitoring would be anticipated to be benefi-
cial. However, the capability of most clinical laboratories
to provide such a service is limited. Therefore, the clin-
ician is forced to extrapolate the available pharmacody-
namic and pharmacokinetic information available to select
a dosage regimen. Due to the lack of published literature
on the effects of critical illness and treatment on the
pharmacokinetics of TMP/SMX, the clinician must at-
tempt to estimate dosing requirements. Similarly, the lack
of data on the impact of obesity on dosing requirements
forces the clinician to base dosing on actual body weight
to ensure achievement of desired drug concentrations.
The urgency of obtaining effective concentrations in a
patient who is critically ill from an infection warrants the
use of doses larger than in patients with limited symptoms
from the infection. By utilizing the limited available data
on pharmacokinetics, pharmacodynamics, and potential
for dose-related toxicities, the following doses are recom-
mended for achieving the desired target concentrations
for potential pathogens in critically ill patients.
For patients with Pneumocystis jovenii, Stenotrophomonas
maltophilia, Burkholderia pseudomallei or Nocardia spp.
infection - 15 mg/kg/day TMP IV or PO (with correspond-
ing 75 mg/kg/day SMX).
(The drug could be given in two divided dosages based
on the pharmacokinetics, but the relationship between
Cmax concentrations and toxicity has been only evaluated
in a limited non-critically ill population [7]. Whether the
toxicity is more closely correlated with the Cmax or total
exposure to the drugs is not known. To potentially
minimize the impact of the Cmax on development of toxic-
ities, the drug can be administered in smaller doses more
frequently, three to four per day.)
For methicillin-resistant Staphylococcus aureus (MRSA)
or extended-spectrum β-lactamase-producing (ESBL)
Enterobacteriaceae - 160 mg TMP IV or PO twice daily
(with corresponding 800 mg SMX).
For patient with renal impairment:
a) Measured or estimated creatinine clearance:
Greater than 30 ml/min - full dose;
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of active SMX may be reduced, relying on TMP
activity only);
Less than 15 ml/min - avoid drug if possible since
the SMX metabolites will accumulate to potentially
toxic concentrations unless dosage reduction in
implemented, which would result in inadequate
active SMX exposure.
b) Hemodialysis-dependency - 7.5 mg/kg after each four
hour hemodialysis session (initial 24 to 48 hours at
15 mg/kg/day).
c) Continuous Ambulatory Peritoneal Dialysis - avoid
drug if possible since the SMX metabolites will
accumulate to potentially toxic concentrations unless
dosage reduction in implemented, which would
result in inadequate active SMX exposure.
d) Continuous Veno-venous Hemodiafiltration or Slow
extended daily hemodialysis - 15 mg/kg/day TMP for
Pneumocystis jovenii and equivalent infections; avoid
underdosing with CVVHDF to avoid inadequate
concentrations.
e) Liver Failure - no dosing adjustment needed.
Conclusions
Limited documentation of appropriate concentrations for
treatment of critically ill patients forces the clinician to
use available pharmacodynamic, toxicologic, and pharma-
cokinetics of both TMP and SMX in determining dosing
regimens for critically ill patients considering organ of
clearance impairment.
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